A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole

NCT04494243 PHASE1 COMPLETED

A study to compare safety, pharmacokinetics and pharmacodynamics of AD-214 10/600mg to Rabeprazole 10mg in healthy volunteers.

Details

Lead sponsor	Addpharma Inc.
Phase	PHASE1
Status	COMPLETED
Enrolment	40
Start date	Fri Aug 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Jan 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Gastroesophageal Reflux Disease

Interventions

• AD-214 10/600mg
• Rabeprazole 10mg

Countries

South Korea